These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 33444325)

  • 1. Viral load care of HIV-1 infected children and adolescents: A longitudinal study in rural Zimbabwe.
    Mapangisana T; Machekano R; Kouamou V; Maposhere C; McCarty K; Mudzana M; Munyati S; Mutsvangwa J; Manasa J; Shamu T; Bogoshi M; Israelski D; Katzenstein D
    PLoS One; 2021; 16(1):e0245085. PubMed ID: 33444325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Community Based Antiretroviral Treatment in Rural Zimbabwe.
    Chimukangara B; Manasa J; Mitchell R; Nyabadza G; Katzenstein D; Masimirembwa C
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1185-1191. PubMed ID: 28899102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Resistance Among Adolescents and Young Adults with Virologic Failure of First-Line Antiretroviral Therapy and Response to Second-Line Treatment.
    Kouamou V; Varyani B; Shamu T; Mapangisana T; Chimbetete C; Mudzviti T; Manasa J; Katzenstein D
    AIDS Res Hum Retroviruses; 2020 Jul; 36(7):566-573. PubMed ID: 32138527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinic-based SAMBA-II vs centralized laboratory viral load assays among HIV-1 infected children, adolescents and young adults in rural Zimbabwe: A randomized controlled trial.
    Kouamou V; Machekano R; Mapangisana T; Maposhere C; Mutetwa R; Manasa J; Shamu T; McCarty K; Munyati S; Mutsvangwa J; Bogoshi M; Israelski D; Katzenstein D
    PLoS One; 2023; 18(2):e0281279. PubMed ID: 36787296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.
    Szubert AJ; Prendergast AJ; Spyer MJ; Musiime V; Musoke P; Bwakura-Dangarembizi M; Nahirya-Ntege P; Thomason MJ; Ndashimye E; Nkanya I; Senfuma O; Mudenge B; Klein N; Gibb DM; Walker AS;
    PLoS Med; 2017 Nov; 14(11):e1002432. PubMed ID: 29136032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief Report: Ritonavir Concentrations in Hair Predict Virologic Outcomes in HIV-Infected Adolescents With Virologic Failure on Atazanavir-Based or Ritonavir-Based Second-Line Treatment.
    Chawana TD; Nhachi CFB; Nathoo K; Ngara B; Okochi H; Louie A; Kuncze K; Katzenstein D; Metcalfe J; Gandhi M;
    J Acquir Immune Defic Syndr; 2021 Oct; 88(2):181-185. PubMed ID: 34117162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of nonsuppressed viral load and associated factors among HIV-positive adults receiving antiretroviral therapy in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017): results from population-based nationally representative surveys.
    Haas AD; Radin E; Hakim AJ; Jahn A; Philip NM; Jonnalagadda S; Saito S; Low A; Patel H; Schwitters AM; Rogers JH; Frederix K; Kim E; Bello G; Williams DB; Parekh B; Sachathep K; Barradas DT; Kalua T; Birhanu S; Musuka G; Mugurungi O; Tippett Barr BA; Sleeman K; Mulenga LB; Thin K; Ao TT; Brown K; Voetsch AC; Justman JE
    J Int AIDS Soc; 2020 Nov; 23(11):e25631. PubMed ID: 33225559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration.
    Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
    Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Provision of HIV viral load testing services in Zimbabwe: Secondary data analyses using data from health facilities using the electronic Patient Monitoring System.
    Apollo T; Takarinda KC; Phillips A; Ndhlovu C; Cowan FM
    PLoS One; 2021; 16(1):e0245720. PubMed ID: 33481931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir, Lamivudine, and Dolutegravir Among Rural Adolescents in Zimbabwe: A Cautionary Tale.
    Kouamou V; Machekano R; Mapangisana T; Maposhere C; Munyati S; Mutsvangwa J; Shamu T; McCarty K; Katzenstein D; Manasa J
    AIDS Res Hum Retroviruses; 2022 Oct; 38(10):774-778. PubMed ID: 35959737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoption of routine virologic testing and predictors of virologic failure among HIV-infected children on antiretroviral treatment in western Kenya.
    Kadima J; Patterson E; Mburu M; Blat C; Nyanduko M; Bukusi EA; Cohen C; Oyaro P; Abuogi L
    PLoS One; 2018; 13(11):e0200242. PubMed ID: 30412576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey.
    Musengimana G; Tuyishime E; Kiromera A; Malamba SS; Mulindabigwi A; Habimana MR; Baribwira C; Ribakare M; Habimana SD; DeVos J; Mwesigwa RCN; Kayirangwa E; Semuhore JM; Rwibasira GN; Suthar AB; Remera E
    Antivir Ther; 2022 Jun; 27(3):13596535221102690. PubMed ID: 35593031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.
    Musoke P; Szubert AJ; Musiime V; Nathoo K; Nahirya-Ntege P; Mutasa K; Williams DE; Prendergast AJ; Spyer M; Walker AS; Gibb DM;
    AIDS; 2015 Aug; 29(13):1623-1632. PubMed ID: 26193705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
    ; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS
    Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
    Hakim JG; Thompson J; Kityo C; Hoppe A; Kambugu A; van Oosterhout JJ; Lugemwa A; Siika A; Mwebaze R; Mweemba A; Abongomera G; Thomason MJ; Easterbrook P; Mugyenyi P; Walker AS; Paton NI;
    Lancet Infect Dis; 2018 Jan; 18(1):47-57. PubMed ID: 29108797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load.
    Kibalama Ssemambo P; Nalubega-Mboowa MG; Owora A; Serunjogi R; Kironde S; Nakabuye S; Ssozi F; Nannyonga M; Musoke P; Barlow-Mosha L
    BMC Pediatr; 2021 Mar; 21(1):139. PubMed ID: 33752636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
    Paton NI; Kityo C; Thompson J; Nankya I; Bagenda L; Hoppe A; Hakim J; Kambugu A; van Oosterhout JJ; Kiconco M; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS;
    Lancet HIV; 2017 Aug; 4(8):e341-e348. PubMed ID: 28495562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.
    Coovadia A; Abrams EJ; Strehlau R; Shiau S; Pinillos F; Martens L; Patel F; Hunt G; Tsai WY; Kuhn L
    JAMA; 2015 Nov; 314(17):1808-17. PubMed ID: 26529159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children.
    Kekitiinwa A; Szubert AJ; Spyer M; Katuramu R; Musiime V; Mhute T; Bakeera-Kitaka S; Senfuma O; Walker AS; Gibb DM;
    Pediatr Infect Dis J; 2017 Jun; 36(6):588-594. PubMed ID: 28505015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.